Monensin

• Description:

  Monensin (Monensin A), an orally active antibiotic, is an ionophore that mediates Na+/H+ exchange. Monensin is a potent Wnt signaling inhibitor. Monensin causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion. Monensin can be used for bacterial, fungal, and parasitic infections research, and shows anticancer effects[1][2][3][4].

• Product Name Alternative:

  Monensin A

• UNSPSC:

  12352005

• Target:

  Antibiotic; Apoptosis; Bacterial; Fungal; Na+/H+ Exchanger (NHE) ; Parasite; Wnt

• Type:

  Natural Products

• Related Pathways:

  Anti-infection; Apoptosis; Membrane Transporter/Ion Channel; Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection

• Assay Protocol:

  https://www.medchemexpress.com/monensin.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C[C@]1 ([C@]2 ([H]) O[C@@] (CC2) ([C@]3 ([H]) O[C@] ([C@@]4 ([H]) O[C@] (O) ([C@@H] (C[C@@H]4C) C) CO) ([H]) C[C@@H]3C) CC) O[C@@]5 (CC1) O[C@] ([C@@H] ([C@H] (C5) O) C) ([H]) [C@@H] (C) [C@@H] (OC) [C@H] (C) C (O) =O

• Molecular Formula:

  C36H62O11

• Molecular Weight:

  670.87

• References & Citations:

  [1]Dayekh K, et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther. 2014 Nov;13 (11) :2559-71.|[2]Tumova L, et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol Cancer Ther. 2014 Apr;13 (4) :812-22. |[3]Youhua Huang, et al. Autophagy Participates in Lysosomal Vacuolation-Mediated Cell Death in RGNNV-Infected Cells. Front Microbiol. 2020 Apr 30:11:790. |[4]Ariel Savina, et al. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic. 2005 Feb;6 (2) :131-43.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Natural Products

• Clinical Information:

  No Development Reported

• Citation 01:

  AAPS PharmSciTech. 2023 Feb 15;24 (2) :69.|Adv Healthc Mater. 2025 May 24:e2500507.|Biochem Pharmacol. 2024 Jan:219:115957.|Clin Exp Immunol. 2024 Mar 12;216 (1) :68-79.|Clin Immunol. 2023 Mar:248:109217.|Int J Parasitol Drugs Drug Resist. 2023 Aug:22:44-51.|J Exp Clin Cancer Res. 2021 Jan 6;40 (1) :16.|Nat Methods. 2024 Feb;21 (2) :259-266.|Oncoimmunology. 2023 Apr 19;12 (1) :2204015.|Redox Biol. 2022 Oct:56:102456.|Signal Transduct Target Ther. 2023 Jul 17;8 (1) :273.|Small. 2021 Dec;17 (50) :e2103984.|Theranostics. 2025 May 25;15 (13) :6329-6346.|Adv Healthc Mater. 2024 Dec 1:e2402976.|bioRxiv. 2023 Jun 25.|bioRxiv. 2023 Sep 12:2023.09.09.557001.|bioRxiv. 2024 Jul 27:2024.07.25.605164.|Cell Death Dis. 2025 Apr 15;16 (1) :301.|Cell Host Microbe. 2025 Jan 8;33 (1) :119-136.e11.|Cell Rep. 2025 Apr 2;44 (4) :115489.|Eur J Med Res. 2025 May 12;30 (1) :378.|Front Microbiol. 2020 Apr 30;11:790.|Int Immunopharmacol. 2023 Sep 1;124 (Pt A) :110865.|J Exp Med. 2023 Mar 6;220 (3) :e20221316.|J Nanobiotechnology. 2025 Jul 3;23 (1) :483.|Nat Commun. 2022 Jul 22;13 (1) :4255.|Nat Commun. 2025 Jul 18;16 (1) :6621.|Nat Commun. 2025 Mar 10;16 (1) :2368.|Proc Natl Acad Sci U S A. 2025 Jul 15;122 (28) :e2501347122.|Research Square Preprint. 2023 Aug 31.|Sci Rep. 2025 Apr 10;15 (1) :12278.|Signal Transduct Target Ther. 2024 Dec 30;9 (1) :367.|SSRN. 2025 Sep 30.|Talanta. 2025 Apr 10:293:128128.

• CAS Number:

  17090-79-8